Sugi Predict

Sugi Predict / Compounds / SCHEMBL805088

SCHEMBL805088

SCHEMBL805088

Cc1ccc2nc(C)sc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.42
▸ RAB9A P51151 5/20 0.41
▸ NPC1 O15118 5/20 0.41
▸ ALDH1A1 P00352 4/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ CYP1A2 P05177 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ CCR1 P32246 1/20 0.37
▸ CCR5 P51681 1/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29733282 0.98 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL1661549 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL30770739 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL30407095 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL5533108 0.78 RAB9A (0.48) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL14970051 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL19454408 0.78 CYP1A2 (0.36) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL31109671 0.78 RAB9A (0.48) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL3160366 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10
SCHEMBL17253548 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023163033-A1 NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF 国立研究開発法人量子科学技術研究開発機構 2023-08-31 — — WO disclosed
EP-3426653-B1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2021-12-15 — — EP disclosed
US-20210095196-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-04-01 — — US disclosed
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA 2020-09-24 — — US disclosed
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY AC IMMUNE SA (CH) 2019-03-07 — — US disclosed
WO-2017175068-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 — — WO disclosed
US-9475783-B2 Antimicrobial agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-10-25 — — US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 — — US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 — — US disclosed
WO-2011136385-A1 BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-03 — — WO disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
US-20110263562-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-27 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
US-20110144104-A1 PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2011-06-16 — — US disclosed
US-20110144104-A1 PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2011-06-16 — — US disclosed
EP-2233493-A1 Macrolides Pfizer Products Inc. (US) 2010-09-29 — — EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
EP-1836211-B1 MACROLIDES PFIZER PROD INC (US) 2010-03-03 — — EP disclosed
WO-2010013078-A2 PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS SANOFI-AVENTIS (FR) 2010-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071450-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN SMN1; SMN2 23/4885RAB9A 906/4885NPC1 1677/4885
US-20200299305-A1 BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY SNCA, PARK7, NLN SMN1; SMN2 23/4885RAB9A 906/4885NPC1 1677/4885
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 SMN1; SMN2 2959/4885RAB9A 1340/4885NPC1 1786/4885
US-20210095196-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES SSB, RO60, OSBP SMN1; SMN2 4645/4885RAB9A 428/4885NPC1 2361/4885
US-20110263562-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SMN1; SMN2 1489/4885RAB9A 3890/4885NPC1 1126/4885
US-20110144104-A1 PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS CCR3, CCR1, CCR4 SMN1; SMN2 3832/4885RAB9A 1965/4885NPC1 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.